Patients at the greatest risk for secondary infections, particularly infections that are resistant to first-line antibiotics, include people who are already vulnerable due to other conditions and diseases—like COVID-19. Because of that, antimicrobial resistance poses a significant additional threat, especially as healthcare systems become overburdened.
It is especially important to focus on prevention methods amid the COVID-19 pandemic—in previous reports of SARS and MERS-CoV infections, AKI developed in 5% to 15% of cases and carried an extremely high (60%-90%) mortality rate.
Hospitalizations with acute kidney injury (AKI) more than quadrupled in the US from 2000-2014 and clinicians are increasingly recognizing AKI as an in-hospital complication of sepsis, heart conditions, and surgery.
It is estimated that one out of every twenty hospitalized patients will contract an HAI. These infections are a significant cause of illness and mortality, and are the source of serious economic consequences for the US health system each year.